Novo Nordisk announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche announced a ...

Arvinas’ cash burn and lack of pipeline candidates hurt its outlook. See why ARVN stock is a sell, despite a healthy cash ...

Arvinas (ARVN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

Arvinas (ARVN) stock faces a downgrade after underwhelming trial data for breast cancer drug vepdegestrant developed with ...

An experimental breast cancer treatment co-developed by Pfizer and Arvinas significantly improved the time some patients ...

A next-generation treatment for breast cancer from Pfizer Inc. and Arvinas Inc. posted disappointing results in a final-stage ...

Arvinas (NASDAQ:ARVN – Get Free Report) was downgraded by analysts at Wedbush from an “outperform” rating to a “neutral” ...

The drug in question, called vepdegestrant, is an oral PROteolysis TArgeting Chimera (PROTAC) ER degrader. The phase 3 study ...

Vepdegestrant did not improve progression-free survival broadly but saw improvements in one specific patient cohort. Arvinas’ ...

Guggenheim analyst Michael Schmidt lowered the firm’s price target on Arvinas (ARVN) to $32 from $57 and keeps a Buy rating on the shares after ...

Goldman Sachs analyst Paul Choi downgraded Arvinas (ARVN) to Neutral from Buy with a price target of $15, down from $70, after the company ...